Abstract
The consistent improvements in hemophilia care seen in the years 1960 to 1980 halted when human immunodeficiency virus (HIV) appeared in the blood supply. In the early 1980s, before HIV virulence was fully understood, a complacent blood therapy industry and its regulators waffled on an appropriate response. As a result, the period between the appearance of HIV and its effective elimination from the blood supply was lengthy and many recipients of blood therapies became infected, with devastating impact on their quality of life, quality of care, and longevity. As the decade wore on, even as they began to better understand the threat, industry and public health officials continued to stall, in part because development of interventions was costly and cumbersome. In order to protect the safety of the blood supply and blood-derived therapies, it must be recognized that new pathogens will continue to emerge. Agencies' and companies' decision-making processes in this regard must therefore be proactive rather than reactive, and should preferably implement a formalized risk-management approach. The ongoing safety of blood therapies and the blood supply will also depend on continued vigilance and research. Finally, the hemophilia communit...Continue Reading
References
Apr 15, 1991·Annals of Internal Medicine·P K Jones, O D Ratnoff
Aug 1, 1985·The Journal of Clinical Investigation·J S McDougalB L Evatt
Jun 27, 1996·The New England Journal of Medicine·G B SchreiberJ J Korelitz
Sep 12, 2000·Haemophilia : the Official Journal of the World Federation of Hemophilia·B EvattN de Bosch
Nov 22, 2000·Annals of Medicine·J M Teitel
Mar 29, 2001·Transfusion·J M SoucieUNKNOWN Hemophilia Surveillance System Project Investigators
Apr 3, 2001·American Journal of Hematology·T L ChorbaB L Evatt
Nov 20, 2002·Vox Sanguinis·C L van der PoelW P Schaasberg
Feb 1, 2003·Haemophilia : the Official Journal of the World Federation of Hemophilia·T Burnouf, M Radosevich
Feb 1, 2003·Haemophilia : the Official Journal of the World Federation of Hemophilia·R WinikoffG-E Rivard
Feb 25, 2003·JAMA : the Journal of the American Medical Association·Michael P BuschGeorge J Nemo
Aug 9, 2003·Expert Opinion on Drug Safety·Kimberly W Schlesinger, Margaret V Ragni
Sep 23, 2003·The New England Journal of Medicine·Roger Y Dodd
Feb 14, 2004·Lancet·C A LlewelynR G Will
May 25, 2004·Expert Opinion on Pharmacotherapy·Natalya AnanyevaEvgueni Saenko
Aug 11, 2004·Lancet·Alexander H PedenJames W Ironside
Citations
Oct 31, 2015·Haemophilia : the Official Journal of the World Federation of Hemophilia·R B ButlerA D Forsberg
Sep 4, 2015·Transfusion·Koen KramerHans L Zaaijer
Feb 20, 2009·Biotechnology Journal·Leopold GrillbergerManfred Reiter
Aug 5, 2011·Haemophilia : the Official Journal of the World Federation of Hemophilia·J EpsteinJ Li-McLeod
Jun 22, 2015·Biologicals : Journal of the International Association of Biological Standardization·Justin McCueHeidi Reichert
Sep 24, 2014·American Journal of Preventive Medicine·Christopher S ParkerLisa C Richardson
Feb 13, 2016·Journal of Medical Ethics·Marcel Verweij, Koen Kramer
Feb 20, 2018·BMC Health Services Research·Jan A GrawRene Burchard
Jul 5, 2008·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Javier BatlleCarlos Aguilar
Jul 19, 2016·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Kanjaksha Ghosh, Kinjalka Ghosh
Dec 21, 2019·BMC Public Health·Emilie B IngvorsenJakob B Bjorner
Oct 27, 2020·Vox Sanguinis·Christina MikkelsenHenrik Ullum